Autolus Therapeutics plc Quarterly Income Tax Expense (Benefit) in USD from Q4 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Autolus Therapeutics plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q4 2017 to Q3 2024.
  • Autolus Therapeutics plc Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $22K.
  • Autolus Therapeutics plc Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $40.5K, a 88.9% decline year-over-year.
  • Autolus Therapeutics plc annual Income Tax Expense (Benefit) for 2023 was -$19.5K, a 107% decline from 2022.
  • Autolus Therapeutics plc annual Income Tax Expense (Benefit) for 2022 was $272K, a 369% increase from 2021.
  • Autolus Therapeutics plc annual Income Tax Expense (Benefit) for 2021 was $58K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $40.5K $22K +$43K Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$2.5K $51K +$11K +27.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$13.5K -$8K +$6K +42.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-17
Q4 2023 -$19.5K -$24.5K -$384K -107% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 $364K -$21K -$16K -320% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $380K $40K +$96K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $284K -$14K +$12K +46.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-17
Q4 2022 $272K $359K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$5K Jul 1, 2022 Sep 30, 2022 10-K 2024-03-21
Q2 2022 -$56K Apr 1, 2022 Jun 30, 2022 10-K 2024-03-21
Q1 2022 -$26K +$5.7M +99.5% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-21
Q1 2021 -$26.2M -$5.72M -$2.03M -54.9% Jan 1, 2021 Mar 31, 2021 6-K 2021-05-06
Q4 2020 -$24.2M -$5.58M -$1.72M -44.4% Oct 1, 2020 Dec 31, 2020 20-F 2023-03-07
Q3 2020 -$22.4M -$7.87M -$3.27M -71.1% Jul 1, 2020 Sep 30, 2020 6-K 2020-11-05
Q2 2020 -$19.2M -$7.02M -$3.75M -114% Apr 1, 2020 Jun 30, 2020 6-K 2020-08-06
Q1 2020 -$15.4M -$3.7M -$275K -8.04% Jan 1, 2020 Mar 31, 2020 6-K 2021-05-06
Q4 2019 -$15.2M -$3.87M -$1.26M -48.4% Oct 1, 2019 Dec 31, 2019 20-F 2022-03-10
Q3 2019 -$13.9M -$4.6M -$2.4M -109% Jul 1, 2019 Sep 30, 2019 6-K 2020-11-05
Q2 2019 -$11.5M -$3.27M -$1.06M -47.7% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-06
Q1 2019 -$10.4M -$3.42M Jan 1, 2019 Mar 31, 2019 6-K 2020-05-07
Q4 2018 -$2.61M -$1.21M -86.5% Oct 1, 2018 Dec 31, 2018 20-F 2021-03-04
Q3 2018 -$2.2M Jul 1, 2018 Sep 30, 2018 6-K 2019-11-07
Q2 2018 -$2.22M Apr 1, 2018 Jun 30, 2018 6-K 2019-08-08
Q4 2017 -$1.4M Oct 1, 2017 Dec 31, 2017 20-F 2019-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.